Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AngioDynamics ( (ANGO) ) has issued an announcement.
At the Annual Meeting of Shareholders held on November 10, 2025, AngioDynamics announced the election of its Board of Directors, with James C. Clemmer and Michael E. Tarnoff, MD, elected as Class I directors until 2028. Additionally, shareholders approved the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending May 31, 2026, and endorsed the executive compensation of the company’s named executive officers.
The most recent analyst rating on (ANGO) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.
Spark’s Take on ANGO Stock
According to Spark, TipRanks’ AI Analyst, ANGO is a Neutral.
AngioDynamics’ overall stock score reflects a mixed outlook. The most significant factor is the company’s financial performance, which is challenged by negative profitability and cash flow issues. However, the technical analysis shows strong momentum, and the positive earnings call with increased guidance provides optimism for future performance. Valuation concerns remain due to the negative P/E ratio and lack of dividend yield.
To see Spark’s full report on ANGO stock, click here.
More about AngioDynamics
AngioDynamics operates in the medical technology industry, focusing on the development and manufacturing of minimally invasive medical devices. The company primarily serves the healthcare sector, providing products for vascular access, peripheral vascular disease, and oncology.
Average Trading Volume: 474,552
Technical Sentiment Signal: Buy
Current Market Cap: $505.9M
For an in-depth examination of ANGO stock, go to TipRanks’ Overview page.